# A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

> **NCT00434278** · PHASE4 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Dornase alfa
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00434278
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** This study was terminated for administrative reasons. There were no safety concerns.
- **Last updated:** 2017-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00434278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00434278, "A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00434278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*